17 July 2026
In plain English
Six days until the FDA's peptide advisory panel votes. No new developments — the panel roster, the staff recommendations against all seven peptides, and the industry opposition are all locked in. The oral presentations filed on June 30 still have not appeared on the FDA's public docket, now 12 business days past filing — well beyond the normal three-to-seven-day posting window. Whether this is bureaucratic lag or deliberate pre-meeting sequestration is unclear. Meanwhile, The Compound's GLP-1 Picks site saw its organic search position improve meaningfully — average ranking jumped from 16.7 to 13.0 over the past week — but affiliate revenue dipped to a single $300 conversion. Quiet day. Two forecasts resolve in six days.
Signal detail
T-6. No new regulatory evidence since briefing-doc publication July 13 and PSM formal opposition July 15. FDA staff recommends against all seven peptides citing not-well-characterized, insufficient human safety data, and unassessed immunogenicity risk. Pro-peptide panel composition remains the dominant variable. Oral presentations filed June 30 still absent from FDA public docket at 12+ business days — outer bound of any normal posting lag. Public comment closes July 22 (5 days). 6 days to resolution.
Same T-6 dynamics. KPV and MOTS-c remain the strongest Cat 1 candidates; TB-500 weakened by PSM tumor acceleration data. 14-member panel enables moderate 2-of-4 outcomes that the prior 3-member panel could not produce. Regulatory convergence week: PCAC July 23 + 503B comment deadline July 30. 6 days to resolution.
Month 19+ post-facility acquisition, within 18–24mo M&A-to-launch base rate. Consumer peptide education campaign active on Instagram. OneTwenty 13+ weeks live with zero FDA enforcement. Simply Wall St coverage notes Hims navigating FDA scrutiny while pressing ahead with peptide strategy. No new launch signals. Next catalysts: PCAC July 23, Q2 earnings August. 167 days to resolution.
No new US adverse events. Regulatory convergence week July 23–30 creates concentrated editorial window where journalists covering PCAC encounter 40% contamination statistics in FDA briefing materials and PSM's citation-ready filing. 78% of reported complications linked to contamination per PSM's formal PCAC comments. 257 days to resolution.
Day 17 post-launch. No enrollment data, no operational failures, no political blowback. Consumer guide ecosystem proliferating: CMS, Humana, Medicare Interactive, MyClearMatch, Medicare.tools all live with eligibility explainers. Zero Medicare-bridge-related queries in GLP-1 Picks GSC — consistent with the program being physician-initiated rather than consumer-searched. First pharmacy claims data expected mid-to-late July. 167 days to resolution.
First-party Katalys: $300/week from 1 conversion (down from $600/2 prior week), sole converter Trim Rx. GSC: 6,242 impressions (+7% WoW), 119 clicks (+3%), average position 13.0 (improved from 16.7 — most significant position gain in weeks). Embody review cluster drives ~60% of all clicks. Zero peptide DTC affiliates in the market. GLP-1 CPA dominance $260–500 vs peptide $0 structural. CagriSema NOT approved — NDA pending per Ro.co (Tier 1); decision expected late 2026. Retatrutide NDA Q4 2026. 167 days to resolution.
Resolutions & upcoming
No forecasts resolved. Two forecasts resolve July 23 (6 days): - `bpc157-pcac-2026` (0.35 — NOT Cat 1) - `pcac-july-multi-peptide` (0.70 — ≥2 of 4 Cat 1)
How Barque got smarter today
- Search position and revenue are decoupled at low authority. GSC position improved 16.7 → 13.0 while Katalys revenue dropped 85% ($2,049 → $300 WoW). At DR ~1.7, GLP-1 Picks is climbing for comparison-intent queries (Embody vs Ro, Embody vs Trim Rx) but converting poorly — 1 conversion from 508 clicks = 0.2% conversion rate. Heuristic: position gains at low domain authority attract research-stage visitors, not purchase-ready patients. Revenue tracks conversion-partner quality and offer availability, not ranking alone.
- Oral presentation docket absence now at 12 business days. Second brief flagging. Worth logging as a process signal for future PCAC-related forecasts. When FDA advisory committee filings miss their 3–7 day public posting window, the delay becomes a first-order signal about FDA staff engagement with the submissions.
- CagriSema misinformation day 5. Ro.co (Tier 1) explicitly states "under FDA NDA review." CNBC and PharmExec describe NDA filed Dec 2025 with decision expected 2026. Platinum Capital claim persists in search results. Fourth brief flagging `glp1picks-update-cagrisema-approval-confirmed` for kill. Operator action overdue.
- Firehose listener zero matches — third consecutive source pack. PCAC hearing in 6 days. Highest-priority operational fix. Escalation stands.
- Sources sampled: FDA.gov (Tier 1), CMS.gov (Tier 1), MedicalXpress (Tier 1), Healio (Tier 1), STAT (Tier 1), DVM360 (Tier 1 animal), Drugs.com (Tier 1), Ro.co (Tier 1), PSM (Tier 2), Simply Wall St (Tier 2), StockTwits (Tier 2). First-party: Katalys, GSC.